Patients with glioblastoma—the deadliest type of primary brain tumor—may potentially benefit from immunotherapy medications called immune checkpoint inhibitors that stimulate an immune response against cancer cells.
Feb 2, 2023
0
30
A combination of chemotherapy and drugs that stimulate the immune system to combat cancer is increasingly used to control progression of the disease in patients. On the other hand, clinical studies show that the combination ...
Jan 30, 2023
0
39
Targeting cellular post-transcription mechanisms in the CD73 ectoenzyme may promote anti-tumor immunity and slow cancer progression in triple-negative breast cancer, according to a Northwestern Medicine study published in ...
Jan 19, 2023
0
43
Immune checkpoint inhibitors are important medications that boost the immune system's response against various cancers, but some patients' cancer cells are unaffected by the drugs or develop resistance during treatment.
Jan 12, 2023
0
62
Even as they've revolutionized cancer treatment, drugs known as immune checkpoint inhibitors can produce a range of adverse, immune-related side effects. In a new study, scientists at Dana-Farber Cancer Institute identify, ...
Dec 16, 2022
0
104
Thanks to advances in cancer therapies, most forms of breast cancer are highly treatable, especially when caught early.
Dec 15, 2022
0
54
Immune checkpoint inhibitors activate the body's immune system against tumors. Although this cancer treatment has shown remarkable success, the patient's chance of responding to the treatment remains unpredictable. Scientists ...
Dec 5, 2022
0
36
A single drug compound simultaneously attacks hard-to-treat prostate cancer on several fronts, according to a new study in mice and human cells. It triggers immune cells to attack, helps the immune cells penetrate the tumor, ...
Nov 23, 2022
0
76
Duke Health researchers have identified a unique process within the environment of deadly brain tumors that drives resistance to immune-boosting therapies and could be targeted to promote the effects of those drugs.
Nov 3, 2022
0
41
A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center and the University of California San Francisco (UCSF) has discovered the underlying cause of gender differences in immunotherapy-associated ...
Nov 2, 2022
0
9
